The role of the tumour microenvironment in the angiogenesis of pituitary tumours
-
Published:2020-09-18
Issue:3
Volume:70
Page:593-606
-
ISSN:1355-008X
-
Container-title:Endocrine
-
language:en
-
Short-container-title:Endocrine
Author:
Marques Pedro, Barry Sayka, Carlsen Eivind, Collier David, Ronaldson Amy, Dorward Neil, Grieve Joan, Mendoza Nigel, Nair Ramesh, Muquit Samiul, Grossman Ashley B., Korbonits MártaORCID
Abstract
Abstract
Purpose
Angiogenesis has been studied in pituitary neuroendocrine tumours (PitNETs), but the role of the tumour microenvironment (TME) in regulating PitNET angiogenesis remains unknown. We aimed to characterise the role of TME components in determining the angiogenetic PitNET profile, focusing on immune cells and tumour-derived cytokines.
Methods
Immune cells were studied by immunohistochemistry in 24 human PitNETs (16 non-functioning-PitNETs (NF-PitNETs) and 8 somatotrophinomas): macrophages (CD68, CD163, HLA-DR), cytotoxic (CD8) and T helper (CD4) lymphocytes, regulatory T cells (FOXP3), B cells (CD20) and neutrophils (neutrophil elastase); endothelial cells were assessed with CD31. Five normal pituitaries (NP) were included for comparison. Microvessel density and vascular morphology were estimated with ImageJ. The cytokine secretome from these PitNETs were assessed on culture supernatants using a multiplex immunoassay panel.
Results
Microvessel density/area was higher in NP than PitNETs, which also had rounder and more regular vessels. NF-PitNETs had vessels of increased calibre compared to somatotrophinomas. The M2:M1 macrophage ratio correlated with microvessel area. PitNETs with more CD4+ T cells had higher microvessel area, while tumours with more FOXP3+ cells were associated with lower microvessel density. PitNETs with more B cells had rounder vessels. Of the 42 PitNET-derived cytokines studied, CCL2, CXCL10 and CX3CL1 correlated with microvessel density and vessel architecture parameters.
Conclusions
M2 macrophages appear to play a role in PitNET neovascularisation, while B, CD4+ and FOXP3+ lymphocytes, as well as non-cellular TME elements such as CCL2, CXCL10 and CX3CL1, may also modulate the angiogenesis of PitNETs.
Funder
Barts and The London Charity
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism
Reference65 articles.
1. P. Marques, M. Korbonits, Genetic aspects of pituitary adenomas. Endocrinol. Metab. Clin. North Am. 46(2), 335–374 (2017). https://doi.org/10.1016/j.ecl.2017.01.004 2. M.E. Molitch, Diagnosis and treatment of pituitary adenomas: a review. JAMA 317(5), 516–524 (2017). https://doi.org/10.1001/jama.2016.19699 3. J. Trouillas, P. Roy, N. Sturm, E. Dantony, C. Cortet-Rudelli, G. Viennet, J.F. Bonneville, R. Assaker, C. Auger, T. Brue, A. Cornelius, H. Dufour, E. Jouanneau, P. Francois, F. Galland, F. Mougel, F. Chapuis, L. Villeneuve, C.A. Maurage, D. Figarella-Branger, G. Raverot; members of, H., A. Barlier, M. Bernier, F. Bonnet, F. Borson-Chazot, G. Brassier, S. Caulet-Maugendre, O. Chabre, P. Chanson, J.F. Cottier, B. Delemer, E. Delgrange, L. Di Tommaso, S. Eimer, S. Gaillard, M. Jan, J.J. Girard, V. Lapras, H. Loiseau, J.G. Passagia, M. Patey, A. Penfornis, J.Y. Poirier, G. Perrin, A. Tabarin, A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 126(1), 123–135 (2013). https://doi.org/10.1007/s00401-013-1084-y 4. F. Barbieri, A. Bajetto, R. Stumm, A. Pattarozzi, C. Porcile, G. Zona, A. Dorcaratto, J.L. Ravetti, F. Minuto, R. Spaziante, G. Schettini, D. Ferone, T. Florio, Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin. Cancer Res. 14(16), 5022–5032 (2008). https://doi.org/10.1158/1078-0432.CCR-07-4717 5. Y. Mei, W.L. Bi, N.F. Greenwald, Z. Du, N.Y. Agar, U.B. Kaiser, W.W. Woodmansee, D.A. Reardon, G.J. Freeman, P.E. Fecci, E.R. Laws Jr, S. Santagata, G.P. Dunn, I.F. Dunn, Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors. Oncotarget 7(47), 76565–76576 (2016). https://doi.org/10.18632/oncotarget.12088
Cited by
27 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|